Protego Biopharma’s lead program is a potential treatment for the rare disease light chain amyloidosis. The startup says the novel mechanism of its oral small molecule should have better outcomes than antibodies from AstraZeneca and Prothena that failed their respective pivotal studies in the disorder earlier this year.
The post Startup Protego Bio Lands $130M for First-in-Class Drug’s Pivotal Test in Rare Plasma Disorder appeared first on MedCity News.
New Work Requirement Adds Red Tape to Missouri’s Snarled Food Aid System
WARRENTON, Mo. — Distributing food stamps soon could get even harder for Missouri’s food aid system, which a federal judge has already called “broken and
